{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:49:06Z","timestamp":1791967746235,"version":"4.3.4"},"update-to":[{"DOI":"10.12688\/hrbopenres.14314.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000}}],"reference-count":37,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["ILP-HSR-2022-006"],"award-info":[{"award-number":["ILP-HSR-2022-006"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010790","name":"Erasmus+","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010790","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["hrbopenresearch.org"],"crossmark-restriction":false},"short-container-title":["HRB Open Res"],"abstract":"<ns3:p>Introduction Discontinuation of psychotropic medication is associated with considerable clinical challenges, including withdrawal symptoms and relapse. Pharmacogenomic testing is increasingly used in clinical practice to optimise pharmacotherapy by guiding drug selection and dosing, however, its role in informing medication discontinuation and tapering strategies remains underexplored. Understanding the influence of genetic variability on withdrawal symptoms could support safer, individualised discontinuation practices. Objective This scoping review aims to map the available evidence on the role of pharmacogenomics on the discontinuation of psychotropic medications. Methods The review will be conducted in accordance with the Joanna Briggs Institute (JBI) methodology for scoping reviews and reported using the PRISMA-ScR checklist. Comprehensive searches will be performed in MEDLINE, EMBASE, CINAHL, Web of Science, and PsycINFO. Studies exploring gene polymorphisms relevant to the discontinuation of psychotropic medications (antidepressants, antipsychotics, mood stabilisers, anxiolytics, hypnotics, stimulants, and opioids) will be considered. Following screening, data will be extracted, and a narrative synthesis will be undertaken to map characteristics of included studies, genes studied, medication classes involved, reported outcomes, and knowledge gaps. Conclusion This review will provide an overview of existing evidence and identify gaps regarding the role of pharmacogenomics in psychotropic medication discontinuation. The findings will help to inform future research on the integration of pharmacogenomics into individualised tapering strategies.<\/ns3:p>","DOI":"10.12688\/hrbopenres.14314.2","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:04:06Z","timestamp":1770725046000},"page":"4","update-policy":"https:\/\/doi.org\/10.12688\/hrbopenres.crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocol"],"prefix":"10.12688","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8481-1442","authenticated-orcid":false,"given":"Natalia","family":"Stollarova","sequence":"first","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences Dublin Trinity College Dublin"},{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy Bratislava Comenius University Bratislava"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crist\u00edn","family":"Ryan","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences Dublin Trinity College Dublin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1571-1772","authenticated-orcid":false,"given":"Greg","family":"Sheaf","sequence":"additional","affiliation":[{"name":"The Library of Trinity College Dublin Trinity College Dublin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Keating","sequence":"additional","affiliation":[{"name":"Pharmacy Department Dublin Stillorgan Saint John of God University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"O\u2019Donoghue","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine Dublin University College Dublin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8778-0112","authenticated-orcid":false,"given":"Cathal","family":"Cadogan","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences Dublin Trinity College Dublin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"115537","DOI":"10.1016\/j.psychres.2023.115537","article-title":"Current strategies for tapering psychiatric drugs: differing recommendations, impractical doses, and other barriers.","volume":"329","author":"J Eserian","year":"2023","journal-title":"Psychiatry Res."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"163-176","DOI":"10.1007\/s40122-019-00135-6","article-title":"Stopping or decreasing opioid therapy in patients on chronic opioid therapy.","volume":"8","author":"J Pergolizzi","year":"2019","journal-title":"Pain Ther."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"38-62","DOI":"10.1016\/j.jad.2018.10.107","article-title":"Barriers and facilitators to discontinuing antidepressant use: a systematic review and thematic synthesis.","volume":"245","author":"E Maund","year":"2019","journal-title":"J. Affect. Disord."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1192\/bjo.2020.6","article-title":"Discontinuing psychotropic drug treatment.","volume":"6","author":"L Tondo","year":"2020","journal-title":"BJPsych Open."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"283-306","DOI":"10.1159\/000506868","article-title":"Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications.","volume":"89","author":"F Cosci","year":"2020","journal-title":"Psychother. Psychosom."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"892-903","DOI":"10.1111\/jcpt.13114","article-title":"Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management.","volume":"45","author":"J Pergolizzi","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1758-1769","DOI":"10.1038\/s41380-024-02782-4","article-title":"Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review.","volume":"30","author":"M Zhang","year":"2025","journal-title":"Mol. Psychiatry."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"108386","DOI":"10.1016\/j.jsat.2021.108386","article-title":"Clinical and psychological factors associated with interdose opioid withdrawal in chronic pain population.","volume":"129","author":"S Rodr\u00edguez-Espinosa","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"116241","DOI":"10.1016\/j.psychres.2024.116241","article-title":"Tolerance, interdose withdrawal symptoms, and craving predict prescription opioid-use disorder severity in chronic pain patients: a three-wave prospective study.","volume":"342","author":"S Rodr\u00edguez-Espinosa","year":"2024","journal-title":"Psychiatry Res."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"108787","DOI":"10.1016\/j.drugalcdep.2021.108787","article-title":"Day-to-day opioid withdrawal symptoms, psychological distress, and opioid craving in patients with chronic pain prescribed opioid therapy.","volume":"225","author":"A Bruneau","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"11-17","DOI":"10.1097\/JCP.0b013e3181c8ae80","article-title":"Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome.","volume":"30","author":"Y Murata","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1397-1406","DOI":"10.2217\/pgs.11.103","article-title":"Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients.","volume":"12","author":"C Chen","year":"2011","journal-title":"Pharmacogenomics."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"195-203","DOI":"10.1159\/000491524","article-title":"Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review.","volume":"87","author":"G Fava","year":"2018","journal-title":"Psychother. Psychosom."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"72-81","DOI":"10.1159\/000370338","article-title":"Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review.","volume":"84","author":"G Fava","year":"2015","journal-title":"Psychother. Psychosom."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"886-894","DOI":"10.1080\/10826084.2024.2306221","article-title":"Characterizing opioid withdrawal experiences and consequences among a community sample of people who use opioids.","volume":"59","author":"K Simpson","year":"2024","journal-title":"Subst. Use Misuse."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"355-361","DOI":"10.3238\/arztebl.2019.0355","article-title":"Antidepressant withdrawal and rebound phenomena.","volume":"116","author":"J Henssler","year":"2019","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"526-535","DOI":"10.1016\/S2215-0366(24)00133-0","article-title":"Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis.","volume":"11","author":"J Henssler","year":"2024","journal-title":"Lancet Psychiatry."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"503-516","DOI":"10.1002\/hup.2429","article-title":"New insights on the antidepressant discontinuation syndrome.","volume":"29","author":"B Harvey","year":"2014","journal-title":"Hum. Psychopharmacol."},{"key":"ref21","article-title":"Quality statement 4: Stopping antidepressants|Depression in adults|Quality standards|NICE."},{"key":"ref22","article-title":"Stopping antidepressants."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"sbaf181","DOI":"10.1093\/schbul\/sbaf181","article-title":"A scoping review of methods, guidelines, and protocols used for dose reduction or discontinuation of antipsychotic medication in people affected by psychotic disorders.","author":"I Jeffares","year":"2025","journal-title":"Schizophr. Bull."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"102507","DOI":"10.1016\/j.eclinm.2024.102507","article-title":"Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review.","volume":"70","author":"J Brandt","year":"2024","journal-title":"EClinicalMedicine."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"185-198","DOI":"10.1093\/MED\/9780190654818.003.0010","article-title":"Deprescribing mood stabilizers.","author":"S Gupta","year":"2019","journal-title":"Deprescribing in Psychiatry."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"80-89","DOI":"10.5694\/mja2.52002","article-title":"Clinical practice guideline for deprescribing opioid analgesics: summary of recommendations.","volume":"219","author":"A Langford","year":"2023","journal-title":"Med. J. Aust."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2575-2586","DOI":"10.1038\/s41380-024-02445-4","article-title":"Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.","volume":"29","author":"C Vinkers","year":"2024","journal-title":"Mol. Psychiatry."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"449-473","DOI":"10.1146\/annurev-genom-111621-102737","article-title":"Advancing pharmacogenomics from single-gene to preemptive testing.","volume":"23","author":"C Haidar","year":"2022","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"343-350","DOI":"10.1038\/nature15817","article-title":"Pharmacogenomics in the clinic.","volume":"526","author":"M Relling","year":"2015","journal-title":"Nature."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1224-1232","DOI":"10.1038\/gim.2017.181","article-title":"Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers.","volume":"21","author":"N Keeling","year":"2019","journal-title":"Genet. Med."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"561-566","DOI":"10.1002\/cpt.3704","article-title":"Navigating pharmacogenomic testing in practice: who to test and when to test.","volume":"118","author":"J Stevenson","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1551-1555","DOI":"10.1007\/s11095-017-2163-x","article-title":"Preemptive panel-based pharmacogenetic testing: the time is now.","volume":"34","author":"K Weitzel","year":"2017","journal-title":"Pharm. Res."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1397-1406","DOI":"10.2217\/pgs.11.103","article-title":"Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients.","volume":"12","author":"C Chen","year":"2011","journal-title":"Pharmacogenomics."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.46658\/JBIMES-24-09","article-title":"Scoping reviews.","author":"M Peters","year":"2024","journal-title":"JBI Manual for Evidence Synthesis."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"953-968","DOI":"10.11124\/JBIES-21-00242","article-title":"Best practice guidance and reporting items for the development of scoping review protocols.","volume":"20","author":"M Peters","year":"2022","journal-title":"JBI Evid Synth."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"3-10","DOI":"10.1097\/XEB.0000000000000277","article-title":"Updated methodological guidance for the conduct of scoping reviews.","volume":"19","author":"M Peters","year":"2021","journal-title":"JBI Evid Implement."},{"key":"ref37","article-title":"Covidence systematic review software, veritas health innovation, Melbourne, Australia."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"M Page","year":"2021","journal-title":"BMJ."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.17605\/OSF.IO\/BYSHX","article-title":"The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocol.","author":"N Stoll\u00e1rov\u00e1","year":"December 13, 2025","journal-title":"Open Science Framework."}],"container-title":["HRB Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/hrbopenresearch.org\/articles\/9-4\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/hrbopenresearch.org\/articles\/9-4\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/hrbopenresearch.org\/articles\/9-4\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:09:21Z","timestamp":1791965361000},"score":1,"resource":{"primary":{"URL":"https:\/\/hrbopenresearch.org\/articles\/9-4\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":37,"URL":"https:\/\/doi.org\/10.12688\/hrbopenres.14314.2","relation":{"has-version":[{"id-type":"doi","id":"10.12688\/hrbopenres.14314.1","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.21956\/hrbopenres.15803.r53418","asserted-by":"subject"},{"id-type":"doi","id":"10.21956\/hrbopenres.15803.r53418","asserted-by":"object"}]},"ISSN":["2515-4826"],"issn-type":[{"value":"2515-4826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"Indexed","URL":"https:\/\/hrbopenresearch.org\/articles\/9-4\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.21956\/hrbopenres.15803.r53418, Ramdas Bhat, Pharmaceutical Sciences, Father Muller Charitable Institutions (Ringgold ID: 79611), Mangaluru, Karnataka, 18 Feb 2026, version 2, indexed","URL":"https:\/\/hrbopenresearch.org\/articles\/9-4\/v2#referee-response-53418","order":0,"name":"referee-response-53418","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.21956\/hrbopenres.15756.r52689, Malcolm Hopwood, University of Melbourne, Melbourne, 22 Jan 2026, version 1, 1 approved, 1 approved with reservations","URL":"https:\/\/hrbopenresearch.org\/articles\/9-4\/v1#referee-response-52689","order":1,"name":"referee-response-52689","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Natalia Stollarova<\/b>; \n<i>Posted: 30 Jan 2026<\/i>; We are very grateful to the reviewer for reviewing our manuscript and for the encouraging comments. We are delighted by the recognition of the relevance and timeliness of the proposed scoping review.  In terms of the reviewer\u2019s query regarding the broad range of psychotropic medications, we were conscious that limiting the focus of the review to certain drug classes could result in very limited findings. Therefore, we have purposefully decided to keep the scope of this review broad.","URL":"https:\/\/hrbopenresearch.org\/articles\/9-4\/v2#referee-comment-3883","order":2,"name":"referee-comment-3883","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"Health Research Board Ireland [ILP-HSR-2022-006]. This work was also supported by the Erasmus+ Programme of the European Union.\r\n\r\nThe funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}